CA3231117A1 - Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases - Google Patents
Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases Download PDFInfo
- Publication number
- CA3231117A1 CA3231117A1 CA3231117A CA3231117A CA3231117A1 CA 3231117 A1 CA3231117 A1 CA 3231117A1 CA 3231117 A CA3231117 A CA 3231117A CA 3231117 A CA3231117 A CA 3231117A CA 3231117 A1 CA3231117 A1 CA 3231117A1
- Authority
- CA
- Canada
- Prior art keywords
- powder
- ray diffraction
- diffraction pattern
- characteristic
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111049581.4 | 2021-09-08 | ||
| CN202111049581.4A CN115772123A (zh) | 2021-09-08 | 2021-09-08 | 固体形式 |
| US202163243813P | 2021-09-14 | 2021-09-14 | |
| US63/243,813 | 2021-09-14 | ||
| PCT/US2022/042905 WO2023039063A1 (en) | 2021-09-08 | 2022-09-08 | Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3231117A1 true CA3231117A1 (en) | 2023-03-16 |
Family
ID=83594511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3231117A Pending CA3231117A1 (en) | 2021-09-08 | 2022-09-08 | Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11814354B2 (https=) |
| EP (1) | EP4399201A1 (https=) |
| JP (1) | JP2024533420A (https=) |
| AU (1) | AU2022342069A1 (https=) |
| CA (1) | CA3231117A1 (https=) |
| TW (1) | TW202334088A (https=) |
| WO (1) | WO2023039063A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US20120101282A1 (en) | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| WO2014180741A1 (en) | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
-
2022
- 2022-09-07 US US17/939,203 patent/US11814354B2/en active Active
- 2022-09-08 AU AU2022342069A patent/AU2022342069A1/en active Pending
- 2022-09-08 EP EP22785823.0A patent/EP4399201A1/en active Pending
- 2022-09-08 JP JP2024515556A patent/JP2024533420A/ja active Pending
- 2022-09-08 WO PCT/US2022/042905 patent/WO2023039063A1/en not_active Ceased
- 2022-09-08 TW TW111134009A patent/TW202334088A/zh unknown
- 2022-09-08 CA CA3231117A patent/CA3231117A1/en active Pending
-
2023
- 2023-10-11 US US18/484,722 patent/US12134599B2/en active Active
-
2024
- 2024-09-27 US US18/898,885 patent/US20250263378A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250263378A1 (en) | 2025-08-21 |
| WO2023039063A1 (en) | 2023-03-16 |
| JP2024533420A (ja) | 2024-09-12 |
| TW202334088A (zh) | 2023-09-01 |
| US11814354B2 (en) | 2023-11-14 |
| US20240300895A1 (en) | 2024-09-12 |
| AU2022342069A1 (en) | 2024-03-14 |
| US20230242485A1 (en) | 2023-08-03 |
| EP4399201A1 (en) | 2024-07-17 |
| US12134599B2 (en) | 2024-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2638023B1 (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same | |
| AU2018373122A1 (en) | Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| CN105189513A (zh) | 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态 | |
| US20250263378A1 (en) | Solid forms | |
| US20240199645A1 (en) | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine | |
| KR20010075445A (ko) | 공지된 브라디키닌 길항제의 유리질 형태 | |
| CA3214211A1 (en) | Macrocyclic azolopyridines | |
| CN115772123A (zh) | 固体形式 | |
| US20250243242A1 (en) | Levodopa tyrosine polymorphs | |
| CN115626917B (zh) | 化合物的晶型及其组合物和用途 | |
| WO2026008074A1 (zh) | 补体因子b抑制剂的晶型、其制备方法及用途 | |
| HK1189878B (en) | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |